Urgent

Angioedema differentiation — histaminergic vs bradykinin-mediated

Bedside algorithm to direct angioedema therapy · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Angioedema divides into histaminergic (mast-cell, responds to adrenaline/antihistamines/steroids) and bradykinin-mediated (ACE-inhibitor, hereditary and acquired C1-INH deficiency, which do not respond to those agents). Rapid classification directs treatment and prevents fatal airway obstruction.

Figures & algorithms

Clinical features
Clinical features

Red flags

  • Voice change, dysphagia, drooling or stridor
  • Rapidly progressive tongue or laryngeal swelling
  • No response to adrenaline/antihistamine/steroid
  • Isolated angioedema without urticaria on an ACE-inhibitor
  • Known hereditary angioedema with facial/airway involvement

Assessment

Differential diagnosis

  • Allergic/histaminergic angioedema (often with urticaria)
  • ACE-inhibitor angioedema (bradykinin-mediated)
  • Hereditary angioedema (C1-INH deficiency)
  • Acquired C1-inhibitor deficiency
  • Idiopathic angioedema

Investigations

  • Clinical: presence of urticaria/itch (favours histaminergic) vs none (favours bradykinin)
  • Response to a trial of antihistamine/adrenaline (bradykinin forms do not respond)
  • C4 level (low in bradykinin-mediated C1-INH disorders)
  • C1-inhibitor level and function, C1q
  • Drug history for ACE-inhibitors, ARBs, gliptins, NSAIDs

Management

  • Prioritise airway assessment in every patient — examine tongue, floor of mouth, uvula and larynx
  • If urticaria/itch present or recent allergen exposure, treat as histaminergic: adrenaline, antihistamine, steroid
  • If no urticaria and on an ACE-inhibitor or with a family history, treat as bradykinin-mediated
  • Stop any ACE-inhibitor/ARB immediately and document
  • Give bradykinin-targeted therapy (icatibant or C1-INH concentrate) for severe or airway-threatening bradykinin angioedema
  • Give a trial of adrenaline even in suspected bradykinin cases if airway is threatened (low risk, may help)
  • Secure the airway early (awake fibreoptic / front-of-neck readiness) if progression
  • Send complement studies and refer to immunology for confirmation

Drugs & doses

Adrenaline IM — 500 mcg (0.5 mL 1:1000) for histaminergic/airway-threatening angioedema, repeat 5 min
Chlorphenamine — 10 mg IV/IM for histaminergic angioedema
Hydrocortisone — 200 mg IV for histaminergic angioedema
Icatibant — 30 mg SC for bradykinin-mediated (HAE/ACE-I) angioedema
C1 esterase inhibitor concentrate — 20 units/kg IV for C1-INH deficiency attacks
Fresh frozen plasma — 2 units IV if specific agents unavailable

Disposition

Admit any airway-threatened or bradykinin-mediated case for monitoring; discharge mild histaminergic cases with antihistamines and immunology follow-up.

Complications & pitfalls

  • Fatal airway obstruction from delayed recognition
  • Inappropriate steroid/antihistamine use in bradykinin forms wasting time
  • Unnecessary intubation if misclassified
  • Recurrence while continuing the culprit ACE-inhibitor
  • Missed underlying lymphoproliferative disease in acquired deficiency

Exam pearls

  • Itch and wheals favour histaminergic; their absence with ACE-inhibitor use or family history favours bradykinin
  • Bradykinin angioedema does not respond to adrenaline, antihistamines or steroids — give icatibant or C1-INH
  • A low C4 is a useful screening clue to C1-inhibitor disorders
  • When uncertain and the airway is threatened, treat for both and prioritise the airway

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.